A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

被引：0
|
作者：
Sunil Sharma
Petronella O. Witteveen
Martijn P. Lolkema
Dagmar Hess
Hans Gelderblom
Syed A. Hussain
Maria G. Porro
Edward Waldron
Sue-zette Valera
Song Mu
机构：
[1] University of Utah,Huntsman Cancer Institute
[2] University Medical Center,Department of Medical Oncology
[3] Klinik für Onkologie und Hämatologie,Kantonsspital St. Gallen
[4] Leiden University Medical Center,Department of Clinical Oncology, K1
[5] University of Liverpool,P
[6] Novartis Pharma AG,The Clatterbridge Cancer Centre NHS, Bebington, Wirral
[7] Novartis Pharmaceutical Corporation,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Renal impairment; Panobinostat; Pan-deacetylase inhibitor; Histone; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：87 / 95
页数：8
相关论文
共 50 条
  • [1] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
    Sharma, Sunil
    Witteveen, Petronella O.
    Lolkema, Martijn P.
    Hess, Dagmar
    Gelderblom, Hans
    Hussain, Syed A.
    Porro, Maria G.
    Waldron, Edward
    Valera, Sue-zette
    Mu, Song
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 87 - 95
  • [2] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Marije Slingerland
    Dagmar Hess
    Sally Clive
    Sunil Sharma
    Per Sandstrom
    Niklas Loman
    Maria G. Porro
    Song Mu
    Edward Waldron
    Sue-zette Valera
    Hans Gelderblom
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1089 - 1098
  • [3] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Slingerland, Marije
    Hess, Dagmar
    Clive, Sally
    Sharma, Sunil
    Sandstrom, Per
    Loman, Niklas
    Porro, Maria G.
    Mu, Song
    Waldron, Edward
    Valera, Sue-zette
    Gelderblom, Hans
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1089 - 1098
  • [4] A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
    Saif, Muhammad Wasif
    Becerra, Carlos R.
    Fakih, Marwan G.
    Sun, Weijing
    Popovic, Lazar
    Krishnamurthi, Smitha
    George, Thomas J.
    Rudek, Michelle A.
    Shepard, Dale R.
    Skopek, Jiri
    Sramek, Vladimir
    Zaric, Bojan
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hamada, Kensuke
    He, Yaohua
    Rosen, Lee
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (03) : 485 - 497
  • [5] A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
    Muhammad Wasif Saif
    Carlos R. Becerra
    Marwan G. Fakih
    Weijing Sun
    Lazar Popovic
    Smitha Krishnamurthi
    Thomas J. George
    Michelle A. Rudek
    Dale R. Shepard
    Jiri Skopek
    Vladimir Sramek
    Bojan Zaric
    Ikuo Yamamiya
    Karim A. Benhadji
    Kensuke Hamada
    Yaohua He
    Lee Rosen
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 485 - 497
  • [6] Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study
    Reid, T. R.
    Takimoto, C. H.
    Verschraegen, C. F.
    Sarantopoulos, J.
    Cheung, W.
    Allen-Freda, E.
    Li, J.
    Xu, Y.
    Ko, J.
    Johri, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
    Sun, Yuping
    Yu, Jinming
    Tolcher, Anthony W.
    Albany, Costantine
    Chaudhry, Arvind
    Dang, Qi
    Ye, Leiguang
    Yang, Fang
    Liu, Baogang
    Sun, Longhua
    Tang, Jianjun
    Xu, Lei
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zhan, Yifan
    Li, Benke
    Hou, Kexin
    Zheng, Yang, Sr.
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors
    Zhang, Jun
    Chavez, Jorge
    Chan, Nancy
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E27 - E27
  • [9] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [10] Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study
    Kondo, Shunsuke
    Katsuya, Yuki
    Yonemori, Kan
    Komuro, Keiko
    Sugeno, Masatoshi
    Kawata, Toshio
    Ghiorghiu, Dana
    Meulendijks, Didier
    Yamamoto, Noboru
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 39
12345